Angle Plc (AGLE)

97.50
+0.50(+0.52%)
  • Volume:
    724,720
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    95.00 - 95.00

AGLE Overview

Prev. Close
97
Day's Range
95-95
Revenue
658K
Open
97
52 wk Range
71.7-163.75
EPS
-0.07
Volume
724,720
Market Cap
229.3M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
1,115,187
P/E Ratio
-
Beta
1.46
1-Year Change
-26.14%
Shares Outstanding
235,181,457
Next Earnings Date
27 Sept 2022
What is your sentiment on Angle?
or
Market is currently closed. Voting is open during market hours.

Angle Plc News

Angle Plc Company Profile

Angle Plc Company Profile

ANGLE plc is a United Kingdom-based specialist medical diagnostic company, which offers products for cancer diagnostics and fetal health. The Company’s lead product is the Parsortix cell separation system, which captures very rare cells from the blood. This includes circulating tumor cells (CTCs) in cancer patient blood even when there is less than one CTC in one billion healthy cells. The Parsortix cell separation system uses a microfluidic technology in the form of a one-time use cassette to capture and then harvest circulating tumor cells (CTCs) from blood. The cassette captures CTCs based on their less deformable nature and larger size compared to other blood components. The Company’s translational research includes ovarian cancer, breast cancer, prostate cancer and small cell lung cancer.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuyBuySellNeutral
Technical IndicatorsBuyStrong BuySellStrong SellStrong Sell
SummaryBuyStrong BuyNeutralStrong SellSell
  • Whilst there is no news the share price will drift off to the £1.00 region-its worth considering adding to holdings if the price sinks somewhat further towards the 80+region.
    0
    • The prognosis for this share price is unbeleivable as the CEO is aiming to dominate the world with blood tests that find and deliver live cancer cells-so no more biopsies !The assumption is the USA FDA approve their M/C application which is expected towards the end of the year.Some ridiculous projections for the sp suggest circa £1500 yes thats one thousand five hundred pounds a share-because their is no competition -suggest check out the website for the full details of patients, posters and peer reviews.Of course the immediate share price will collapse and recover if no FDA approval-nevertheless a holding of a couple of thousand shares will give £3million in a very short time IF APPROVED.Many years of trading and I have never seen anything like this.
      0